This Software Stock Is Down 35% but Here's Why It Just Became a $4 Million Bet

Formula Growth established a new position in monday.com, acquiring 20,000 shares valued at nearly $3.9 million as of Sept. 30 (representing ~1.4% of its reportable AUM and not among its top-five holdings). monday.com reported solid third-quarter fundamentals: revenue of $316.9M (+26% YoY), non-GAAP operating income of $47.5M with 15% margins, free cash flow of $92.3M, more than $1.5B in cash, and remaining performance obligations of $747M; shares trade at $147.08 and are down ~35% over the past year. The filing signals cautious institutional interest amid improving SaaS metrics and weak recent price performance, but the position size and disclosure are unlikely to be market-moving.

Analysis

Market structure: monday.com (MNDY) is positioned to win incremental enterprise wallet share as large customers (> $100k) rose ~50% YoY and RPO is +36% to $747M, implying stickier, higher-ACV demand that should support pricing power vs SMB-focused rivals. Direct winners: MNDY, partners selling integrations, and SaaS multiples re-rating on FCF conversion; losers: point-solution vendors and legacy on-prem tools losing renewals. Cross-asset: further derating in collaboration names would push tech equity beta down, modestly tighten IG flows and lift equity option vols; FX matters if >30% revenue offshore.

Risk assessment: Tail risks include enterprise IT budget cuts (high-impact in a 6–18 month slowdown), accelerated competitive price-matching by Atlassian/Microsoft, or a material customer churn cohort >5% of ARR. Near-term (days–weeks) risk is headline-driven volatility around earnings/guidance; medium-term (3–12 months) is execution on enterprise expansion and margin sustainability; long-term depends on TAM penetration and nonlinear gross retention. Hidden dependency: RPO concentration and any single large account >3–5% ARR could flip guidance.

trade implications: Direct long: initiate a 1.5–3.0% portfolio position in MNDY exposure—prefer staged buys at $120–$140 and add beneath $100; target 12–24 month IRR assuming multiples re-rate from ~6x revenue to 8–10x if growth + margins persist. Pair trade: long MNDY / short TEAM to isolate re-rating risk (size equal dollar, rebalance monthly) because TEAM is pricier and more exposed to enterprise workflow overlap. Options: buy 12–18 month LEAP calls (Jan 2027 120C) sized for 0.5–1% portfolio risk and sell near-term calls to fund premium if implied vol >40%. Exit/stop: trim if non-GAAP margin falls >500bps QoQ or net new ARR growth decelerates >300bps sequentially.

contrarian angles: The market may be overlooking durability of FCF ($92M TTM) and $1.5B cash cushion—this supports buybacks or M&A optionality if valuation stays depressed. Reaction could be overdone: a 35% 12-month price decline has priced in a severe downside; if enterprise seat expansion continues, a 30–50% upside re-rate is plausible within 12–24 months. Unintended risk: a large strategic discounting push by competitors to blunt enterprise wins could force temporary margin compression before re-acceleration.

Key Decisions for Investors

• Establish a staged long in MNDY equal to 1.5–3.0% of portfolio: initial 50% tranche at $135–147, add second tranche at $120–135, final add-via-dip at < $100. Set tactical stop-loss to cut to half size if price < $90 or if YoY net new ARR growth falls >300bps sequentially.
• Implement a relative-value pair: go long MNDY and short TEAM (equal dollar notional) sized to 1% net portfolio exposure to capture potential re-rate vs larger incumbent; rebalance monthly and close if spread narrows <10% or widens >40% against thesis.
• Use options to asymmetrically express conviction: buy Jan 2027 LEAP 120 calls sized to 0.5–1.0% portfolio risk and sell 2–3 month covered calls when IV >40% to fund premium. Alternatively, buy 3–6 month puts (protective hedge) if you already hold shares and implied vol <60%.
• Reduce cyclical small-cap SaaS exposure by 1–2% in favor of MNDY if enterprise metrics (customers >$100k and RPO) continue to accelerate for two consecutive quarters; reallocate proceeds from low-FCF names with FCF margin <5%.